
|Slideshows|September 30, 2016
Neuro News Roundup: Potential MS Therapies
Author(s)Mark L. Fuerst
Three new multiple sclerosis studies show the promise of two drugs, amiselimod and alemtuzumab, as treatments and one, arbaclofen, for spasticity.
Advertisement
Amiselimod, a second generation spin-off of fingolimod, may be a new potential treatment in MS and potentially other immune-mediated inflammatory diseases. Alemtuzumab may be a useful addition to the armamentarium as first-line treatment for relapsing-remitting MS (RRMS). Arbaclofen extended-release tablets may be more effective at decreasing spasticity related to MS than the commonly used spasticity-fighting drug baclofen.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Orexin Agonist Oveporexton for Narcolepsy Type 1
2
FDA Grants RMAT Designation to Sasineprocel for Parkinson Disease
3
FDA Accepts SL1009 Resubmission for PDCD, Sets December PDUFA Date
4
High-Dose N-Acetyl Cysteine Associated With Reduced GFAP Levels in Phase 2 Progressive MS Study
5
















